LinkedIn·Thursday, 20 August 2026·6d ago
The biggest risk in vaccine development isn’t failure. It’s choosing the wrong pathway. As Laurence De Moerlooze highlights, when Phase 3…
P95
20,258 followers
The biggest risk in vaccine development isn’t failure. It’s choosing the wrong pathway.
As Laurence De Moerlooze highlights, when Phase 3 trials aren’t feasible, early strategic decisions can define the success of your entire program.
Pathway selection impacts timelines, costs, and regulatory acceptance, and getting it wrong often means going back to the start.
At P95 Julius Clinical, we help teams make the right call early and move forward with confidence.
👉 Book a meeting with our team to discuss your development strategy: https://lnkd.in/dFgFqXV2
♥ 6
View on LinkedIn Cross-referenced
Related on the wire
At P95 Julius Clinical, we are proud of our people, and we invest in them! Our Africa team includes more than 100 permanent team members…
See you at ERS Congress 2026 in Barcelona! 🌍 We are pleased to share that Leyla Kragten-Tabatabaie and Omar Koussa from our team will be…
We're #hiring a new Expert Modeller (remote, full-time) in European Union. Apply today or share this post with your network.
We're #hiring a new Inside Sales - CRO in European Union. Apply today or share this post with your network.
We're hiring an Expert Modeller to join our Real-World Evidence team and help shape and deliver advanced statistical modelling solutions…
We are excited to see our very own Kaatje Bollaerts featured on an expert panel at ISPE later this month. Together with fellow panelists,…